title: Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intravitreal ranibizumab in patients with choroidal neovascularisation secondary to pathological myopia (myopic CNV). Data are from a pre-planned, 6-month interim analysis.
  
  
  METHODS
  Phase II, open-label, single arm, multicentre, 12-month study, recruiting patients (aged ≥18 years) with active primary or recurrent subfoveal or juxtafoveal myopic CNV, with a best-corrected visual acuity (BCVA) score of 24-78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the study eye and a diagnosis of high myopia of at least -6 dioptres. Patients received 0.5 mg ranibizumab administered intravitreally to the study eye, followed by monthly injections given as needed (based on a predefined algorithm) for up to 11 months.
  
  
  RESULTS
  At 6 months, mean BCVA improved from baseline by 12.2 letters, as did central macular thickness (in this interim analysis defined as a measure of either central subfield macular thickness or centre point macular thickness) from baseline by 108 μm in the 48 study eyes of 48 patients. Fewer patients had centre-involving intraretinal oedema (13.0% vs 91.5%), intraretinal cysts (10.9% vs 57.4%), or subretinal fluid (13.0% vs 66.0%) at 6 months than at baseline. Patients received a mean of 1.9 retreatments, were satisfied with ranibizumab treatment, and well being was maintained. No new safety signals were identified.
  
  
  CONCLUSIONS
  Results from the planned interim analysis support the role of ranibizumab in the treatment of myopic CNV, with excellent efficacy achieved with a low number of injections and few serious adverse events.
authors: Moorfields Eye Hospital, London, UK. Adnan.Tufail@moorfields.nhs.uk
authors: A
authors: A
authors: Tufail
authors: P J
authors: PJ
authors: Patel
authors: S
authors: S
authors: Sivaprasad
authors: W
authors: W
authors: Amoaku
authors: A C
authors: AC
authors: Browning
authors: M
authors: M
authors: Cole
authors: R
authors: R
authors: Gale
authors: S
authors: S
authors: George
authors: A J
authors: AJ
authors: Lotery
authors: M
authors: M
authors: Majid
authors: M
authors: M
authors: McKibbin
authors: G
authors: G
authors: Menon
authors: Y
authors: Y
authors: Yang
authors: C
authors: C
authors: Andrews
authors: C
authors: C
authors: Brittain
authors: A
authors: A
authors: Osborne
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D017060:Patient Satisfaction; D000069579:Ranibizumab; D006113:United Kingdom; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab